Effects of human cytomegalovirus on monocyte survival and differentiation
人巨细胞病毒对单核细胞存活和分化的影响
基本信息
- 批准号:8894196
- 负责人:
- 金额:$ 40.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2017-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAcuteAntiviral AgentsApoptosisApoptoticAtherosclerosisBCL2 geneBackBindingBlood CirculationBypassCell DeathCell Differentiation processCellsChronicCo-ImmunoprecipitationsCytomegalovirusCytomegalovirus InfectionsDevelopmentDifferentiation InducerDiseaseEpidermal Growth Factor ReceptorEtiologyFamilyFamily memberGenesGenetic TranscriptionGlycoproteinsHSPB1 geneHealthHeat Shock Protein 27HematogenousHourImmunocompetentImmunocompromised HostIndividualInfectionInfiltrationInflammationInflammatoryInflammatory Bowel DiseasesIntegrinsLeadLifeLigandsMass Spectrum AnalysisMediatingMicroRNAsModelingMolecularMolecular Mechanisms of ActionMorbidity - disease rateMyelogenousMyeloid CellsNuclear TranslocationOrganOrgan failureOutputPathogenesisPatientsPeripheralPharmacologic SubstancePhosphatidylinositolsPhosphotransferasesPlayProcessProtein FamilyProteinsRegulationRoleSignal PathwaySignal TransductionSiteStagingStaining methodStainsTestingTherapeuticTimeTissuesTransplant RecipientsUse of New TechniquesViralViral PhysiologyViral ProteinsVirusVirus Replicationannexin A5caspase-3cell growth regulationcellular targetingdesignimmunosuppressedinhibitor/antagonistinositol-1,4,5-trisphosphate 5-phosphataseleukemiamacrophagemeetingsmonocytemortalitymutantneonateneutralizing antibodynovelprotein expressionprotein protein interactionreceptorresearch studysmall molecule
项目摘要
DESCRIPTION (provided by applicant): Human cytomegalovirus (HCMV) infection is generally asymptomatic in immunocompetent individuals, although HCMV is a primary viral candidate in the etiology of several chronic inflammatory diseases including atherosclerosis and inflammatory bowel disease. In immunocompromised individuals, such as neonates, AIDS patients, and transplant recipients, HCMV infection can lead to acute multi-organ inflammation resulting in significant morbidity and mortality. Inflammatory organ diseases associated with a HCMV infection is a direct consequence of the systemic viral spread to and infection of multiple organ sites that occur during either asymptomatic or symptomatic infections. Monocytes are responsible for delivering the virus into tissues and play a central role in the inflammatory state
of infected organs. However, because anti-apoptotic viral proteins are not expressed during the early stages of infection, it remains unclear how HCMV simultaneously promotes the survival and pro-inflammatory differentiation of these short-lived cells. We hypothesize that HCMV stimulates a unique cellular anti-apoptotic reprogramming specifically designed to meet the viability needs of differentiating infected monocytes, which will be tested in 3 separate aims. Aim
1 will delineate which viral glycoprotein and cellular receptor interactions occurring during viral
entry are responsible for the rapid block of monocyte apoptosis. Neutralizing antibodies and pharmaceutical inhibitors will be used individually or in different combinations to dissect the rol of each viral ligand and cellular receptor interaction in promoting the survival of HCMV-infected monocytes. Aim 2 will determine how HCMV concurrently drives the long-term survival and the pro-inflammatory differentiation of infected monocytes. Mutant viruses and anti-miRs [bind and inhibit microRNAs (miRNAs)] will be used to neutralize the activity of viral and cellular miRNAs during infection of monocytes. Monocyte survival and differentiation will then be examined by Annexin V staining and Affymetrix microarray gene analysis, respectively. Aim 3 will identify the molecular mechanism of action and therapeutic potential of targeting cellular anti-apoptotic Bcl-2 family proteins induced during HCMV infection of monocytes. To define the mode of action of virally induced cellular anti-apoptotic proteins, co-immunoprecipitation experiments will be done along with mass spectrometry to globally identify new and unique protein-protein interactions specific to HCMV-infected monocytes. BH3 profiling, a new technique used for predicting the sensitivity of cells to small-molecule inhibitors against anti-apoptotic Bcl-2 family members, will
be used to determine the antiviral potential of targeting cellular Bcl-2 family survival proteins i order to direct infected monocytes towards cell death. These studies will increase our understanding on the pathogenesis and dissemination of HCMV, evaluate new antiviral strategies that target infected cells rather than the virus directly, and provide a proof-of-princile for the use of BH3 profiling to predict the efficacy of Bcl- 2 family small-molecule antagonists at
eliminating specific virus and cell infection combinations.
描述(由申请人提供):尽管 HCMV 是多种慢性炎症性疾病(包括动脉粥样硬化和炎症性肠病)病因学中的主要候选病毒,但在免疫功能正常的个体中,人巨细胞病毒(HCMV)感染通常无症状。在免疫功能低下的个体中,例如新生儿、艾滋病患者和移植受者,HCMV 感染可导致急性多器官炎症,导致显着的发病率和死亡率。与 HCMV 感染相关的炎症器官疾病是无症状或有症状感染期间发生的全身性病毒扩散到多个器官部位并感染的直接后果。单核细胞负责将病毒输送到组织中,并在炎症状态中发挥核心作用
受感染的器官。然而,由于抗凋亡病毒蛋白在感染早期并不表达,因此目前尚不清楚 HCMV 如何同时促进这些短命细胞的存活和促炎分化。我们假设 HCMV 会刺激一种独特的细胞抗凋亡重编程,这种重编程是专为满足区分受感染单核细胞的活力需求而设计的,这将在 3 个不同的目标中进行测试。目的
图1将描述病毒感染过程中发生的病毒糖蛋白和细胞受体相互作用
进入负责快速阻止单核细胞凋亡。中和抗体和药物抑制剂将单独或以不同的组合使用,以剖析每种病毒配体和细胞受体相互作用在促进 HCMV 感染的单核细胞存活中的作用。目标 2 将确定 HCMV 如何同时驱动受感染单核细胞的长期存活和促炎分化。突变病毒和抗 miR [结合并抑制 microRNA (miRNA)] 将用于中和单核细胞感染期间病毒和细胞 miRNA 的活性。然后分别通过膜联蛋白 V 染色和 Affymetrix 微阵列基因分析检查单核细胞的存活和分化。目标 3 将确定单核细胞 HCMV 感染过程中诱导的靶向细胞抗凋亡 Bcl-2 家族蛋白的分子作用机制和治疗潜力。为了确定病毒诱导的细胞抗凋亡蛋白的作用模式,将与质谱一起进行免疫共沉淀实验,以全面鉴定针对 HCMV 感染的单核细胞的新的、独特的蛋白质-蛋白质相互作用。 BH3 分析是一种新技术,用于预测细胞对抗凋亡 Bcl-2 家族成员的小分子抑制剂的敏感性。
可用于确定靶向细胞 Bcl-2 家族存活蛋白的抗病毒潜力,以引导受感染的单核细胞死亡。这些研究将增进我们对 HCMV 发病机制和传播的理解,评估针对受感染细胞而不是直接针对病毒的新抗病毒策略,并为使用 BH3 分析预测 Bcl-2 的功效提供原理证明。家族小分子拮抗剂
消除特定的病毒和细胞感染组合。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Human Cytomegalovirus Induces an Atypical Activation of Akt To Stimulate the Survival of Short-Lived Monocytes.
人类巨细胞病毒诱导 Akt 非典型激活,刺激短命单核细胞的存活。
- DOI:
- 发表时间:2016-07-15
- 期刊:
- 影响因子:0
- 作者:Cojohari, Olesea;Peppenelli, Megan A;Chan, Gary C
- 通讯作者:Chan, Gary C
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gary Ching Tao Chan其他文献
Gary Ching Tao Chan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gary Ching Tao Chan', 18)}}的其他基金
Targeting Nuclear HSF1 as a Novel Anti-HCMV Strategy
靶向核 HSF1 作为一种新型抗 HCMV 策略
- 批准号:
10656697 - 财政年份:2023
- 资助金额:
$ 40.25万 - 项目类别:
Mechanisms of HCMV-induced monocyte-to-macrophage differentiation.
HCMV 诱导单核细胞向巨噬细胞分化的机制。
- 批准号:
10057351 - 财政年份:2018
- 资助金额:
$ 40.25万 - 项目类别:
Mechanisms of HCMV-induced monocyte-to-macrophage differentiation.
HCMV 诱导单核细胞向巨噬细胞分化的机制。
- 批准号:
10295787 - 财政年份:2018
- 资助金额:
$ 40.25万 - 项目类别:
Mechanisms of HCMV-induced monocyte-to-macrophage differentiation.
HCMV 诱导单核细胞向巨噬细胞分化的机制。
- 批准号:
10509383 - 财政年份:2018
- 资助金额:
$ 40.25万 - 项目类别:
相似国自然基金
剪接因子U2AF1突变在急性髓系白血病原发耐药中的机制研究
- 批准号:82370157
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
IKZF1-N159Y/S热点突变在急性白血病中的致病机制研究
- 批准号:82300168
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
NMNAT1上调B7-H3介导急性早幼粒细胞白血病免疫逃逸的作用和机制研究
- 批准号:82300169
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
支链氨基酸转氨酶1在核心结合因子急性髓细胞白血病中的异常激活与促进白血病发生的分子机制研究
- 批准号:82370178
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
SRSF3/LRP5/Wnt信号通路在急性淋巴细胞白血病中的作用及机制研究
- 批准号:82370128
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Hepatotoxic mechanisms of anti-HIV- and anti-COVID-19 drugs and substance use disorders
抗 HIV 和抗 COVID-19 药物和物质使用障碍的肝毒性机制
- 批准号:
10684434 - 财政年份:2023
- 资助金额:
$ 40.25万 - 项目类别:
Development of rotavirus-based enterotoxigenic Escherichia coli dual vaccines
基于轮状病毒的产肠毒素大肠杆菌双重疫苗的研制
- 批准号:
10741541 - 财政年份:2023
- 资助金额:
$ 40.25万 - 项目类别:
Identifying human neuron IFN-γ dependent anti-Toxoplasma gondii responses
识别人类神经元 IFN-γ 依赖性抗弓形虫反应
- 批准号:
10619781 - 财政年份:2023
- 资助金额:
$ 40.25万 - 项目类别:
Therapeutic targets in gammaherpesvirus infection
伽马疱疹病毒感染的治疗靶点
- 批准号:
10296371 - 财政年份:2021
- 资助金额:
$ 40.25万 - 项目类别:
Sex difference in intestinal immune dysfunction, SHIV infection and reservoir
肠道免疫功能障碍、SHIV感染和储存者的性别差异
- 批准号:
10327456 - 财政年份:2021
- 资助金额:
$ 40.25万 - 项目类别: